Altre lingue EyePoint Pharmaceuticals, Inc.

Azioni

EYPT

US30233G2093

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 29/04/2024			Variaz. 5gg	Var. 1 gen.
17,63 ^USD	+5,25%		+4,01%	-23,71%

02/04	EyePoint Pharmaceuticals, Inc. amplia il Comitato Scientifico Consultivo	CI
07/03	Aggiornamento settoriale: titoli del settore sanitario misti prima della campana di giovedì	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	17/04
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	16/04
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists	02/04
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	02/04
EyePoint Pharmaceuticals : Investor Presentation March 2024	22/03
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	18/03
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	18/03
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	07/03
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell	07/03
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q4 Revenue $14M	07/03
EyePoint Pharmaceuticals: Q4 Earnings Snapshot	07/03
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments	07/03
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
North American Morning Briefing : Powell Still in -2-	07/03
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	04/03
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer	04/03
EyePoint Pharmaceuticals, Inc. Announces Executive Changes	04/03
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024	29/02
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences	27/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue EyePoint Pharmaceuticals, Inc.

Azioni

EYPT

US30233G2093

Altre lingue

Filtri